266 related articles for article (PubMed ID: 26041469)
21. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.
Wolfson LJ; Daniels VJ; Pillsbury M; Kurugöl Z; Yardimci C; Kyle J; Dinleyici EC
PLoS One; 2019; 14(8):e0220921. PubMed ID: 31408505
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
23. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England.
van Hoek AJ; Melegaro A; Zagheni E; Edmunds WJ; Gay N
Vaccine; 2011 Mar; 29(13):2411-20. PubMed ID: 21277405
[TBL] [Abstract][Full Text] [Related]
24. Universal varicella vaccination: efficacy trends and effect on herpes zoster.
Goldman GS
Int J Toxicol; 2005; 24(4):205-13. PubMed ID: 16126614
[TBL] [Abstract][Full Text] [Related]
25. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
Ouwens MJ; Littlewood KJ; Sauboin C; Téhard B; Denis F; Boëlle PY; Alain S
Clin Ther; 2015 Apr; 37(4):816-829.e10. PubMed ID: 25726457
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
27. Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study.
Horn J; Damm O; Greiner W; Hengel H; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Karch A; Mikolajczyk RT
BMC Med; 2018 Jan; 16(1):3. PubMed ID: 29316913
[TBL] [Abstract][Full Text] [Related]
28. Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: A systematic review.
Hodgkinson B; Wang T; Byrnes J; Scuffham P
Vaccine; 2021 Mar; 39(9):1370-1382. PubMed ID: 33551300
[TBL] [Abstract][Full Text] [Related]
29. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
31. Point-Counterpoint: The Hope-Simpson Hypothesis and Its Implications Regarding an Effect of Routine Varicella Vaccination on Herpes Zoster Incidence.
Harpaz R; van Hoek AJ
J Infect Dis; 2018 Sep; 218(suppl_2):S57-S62. PubMed ID: 30247602
[TBL] [Abstract][Full Text] [Related]
32. The cost-effectiveness of varicella vaccination in Canada.
Brisson M; Edmunds WJ
Vaccine; 2002 Jan; 20(7-8):1113-25. PubMed ID: 11803072
[TBL] [Abstract][Full Text] [Related]
33. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
34. [Immunization of adults against varicella and herpes zoster].
Hanslik T; Blanchon T; Alvarez FP
Rev Med Interne; 2007 Mar; 28(3):166-72. PubMed ID: 17270316
[TBL] [Abstract][Full Text] [Related]
35. What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model.
Rafferty ERS; McDonald W; Osgood ND; Doroshenko A; Farag M
Value Health; 2021 Jan; 24(1):50-60. PubMed ID: 33431153
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of varicella vaccination programs: an update of the literature.
Rozenbaum MH; van Hoek AJ; Vegter S; Postma MJ
Expert Rev Vaccines; 2008 Aug; 7(6):753-82. PubMed ID: 18665775
[TBL] [Abstract][Full Text] [Related]
37. Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015.
Choi JK; Park SH; Park S; Choi SM; Kim SH; Lee DG; Yoo JH; Choi JH; Kang JH
Hum Vaccin Immunother; 2019; 15(11):2554-2560. PubMed ID: 31008679
[No Abstract] [Full Text] [Related]
38. Global impact of varicella vaccination programs.
Varela FH; Pinto LA; Scotta MC
Hum Vaccin Immunother; 2019; 15(3):645-657. PubMed ID: 30427766
[TBL] [Abstract][Full Text] [Related]
39. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.
van Lier A; van Hoek AJ; Opstelten W; Boot HJ; de Melker HE
BMC Health Serv Res; 2010 Aug; 10():237. PubMed ID: 20707884
[TBL] [Abstract][Full Text] [Related]
40. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
